Technical Analysis for MEIP - MEI Pharma, Inc.

Grade Last Price % Change Price Change
grade C 3.07 1.99% 0.06
MEIP closed up 1.99 percent on Tuesday, March 19, 2019, on 31 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical MEIP trend table...

Date Alert Name Type % Chg
Mar 19 NR7 Range Contraction 0.00%
Mar 19 Inside Day Range Contraction 0.00%
Mar 18 MACD Bearish Signal Line Cross Bearish 1.99%
Mar 18 Shooting Star Candlestick Bearish 1.99%
Mar 18 Down 3 Days in a Row Weakness 1.99%
Mar 15 20 DMA Support Bullish 0.66%
Mar 14 Doji - Bearish? Reversal -0.32%
Mar 13 MACD Bullish Signal Line Cross Bullish -0.65%
Mar 13 Up 3 Days in a Row Strength -0.65%
Mar 12 MACD Bearish Signal Line Cross Bearish 2.33%

Older signals for MEIP ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
MEI Pharma, Inc., a development stage oncology company, focuses on the clinical development of therapeutics for the treatment of cancer. It develops various lead drug candidates, including ME-143 that has completed Phase I clinical trials in patients with refractory solid tumors; ME-344, an active metabolite of NV-128, which is in Phase I clinical trials in patients with solid refractory tumors; and Pracinostat, an orally histone deacetylase inhibitor that has completed various Phase I clinical trials in patients with hematologic disorders. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited. MEI Pharma, Inc. (NasdaqCM:MEIP) operates independently of Novogen Limited as of December 03, 2012.
Medicine Cancer Clinical Medicine Treatment Of Cancer Virotherapy Seattle Genetics Kite Pharma Hematologic Disorders Refractory Solid Tumors
Is MEIP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.14
52 Week Low 1.82
Average Volume 195,115
200-Day Moving Average 3.463
50-Day Moving Average 2.8516
20-Day Moving Average 2.9675
10-Day Moving Average 3.023
Average True Range 0.1719
ADX 20.98
+DI 20.2229
-DI 11.525
Chandelier Exit (Long, 3 ATRs ) 2.7584
Chandelier Exit (Short, 3 ATRs ) 3.2257
Upper Bollinger Band 3.2228
Lower Bollinger Band 2.7122
Percent B (%b) 0.7
BandWidth 17.206403
MACD Line 0.0678
MACD Signal Line 0.0706
MACD Histogram -0.0028
Fundamentals Value
Market Cap 113.4 Million
Num Shares 36.9 Million
EPS 0.07
Price-to-Earnings (P/E) Ratio 43.86
Price-to-Sales 4.35
Price-to-Book 1.98
PEG Ratio 23.80
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.21
Resistance 3 (R3) 3.21 3.15 3.19
Resistance 2 (R2) 3.15 3.11 3.15 3.18
Resistance 1 (R1) 3.11 3.09 3.13 3.12 3.17
Pivot Point 3.06 3.06 3.07 3.06 3.06
Support 1 (S1) 3.02 3.02 3.04 3.02 2.97
Support 2 (S2) 2.96 3.00 2.96 2.96
Support 3 (S3) 2.92 2.96 2.95
Support 4 (S4) 2.93